Immune activation in the interface between innate immunity and adaptive response:in vitro studies and therapeutical implications

  • G. Ristori
  • A. Perna
  • C. Montesperelli
  • L. Battistini
  • R. Bomprezzi
  • S. Cannoni
  • G. Borsellino
  • C. Pozzilli
  • C. Buttinelli
  • M. Salvetti
Conference paper


In multiple sclerosis (MS), as well as in other putatively T cell mediated diseases, much attention has been devoted to possible dysregulations at the level of the adaptive immune response, with particular emphasis on the search for potential T lymphocyte autoantigens. These investigations have been, in many cases, unrewarding. One reason may be that T cells are not the key players in self-nonself discrimination: T cell receptors (TCR) have randomly generated specificities that, for this reason, cannot determine the origin and biological context of their ligands [1]. It is becoming increasingly evident that this task is better carried out by the innate immune system that relies on germline-encoded receptors which bind to invariant molecules shared by large groups of microorganisms. These structures (techoic acids, lipopolysaccharides (LPS), double-stranded RNA, mannans) are therefore readily recognized as markers of infection by the innate immune system that instructs the adaptive response accordingly [2]. Based on this evidence, it is now clear that the correct functioning of innate and adaptive immunity as well as their balanced interaction are essential for a physiological immune response [3]. This has prompted much of the recent research focused on the interface between these two arms of the immune system in autoimmunity.


Multiple Sclerosis Innate Immune System Multiple Sclerosis Plaque Extracellular Matrix Glycoprotein Cell Mediate Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Medzhitov R, Janeway CA Jr (1997) Innate immunity: the virtues of a non-clonal system of recognition. Cell 91: 295–298PubMedCrossRefGoogle Scholar
  2. 2.
    Fearon DT, Locksley RM (1996) The instructive role of innate immunity in the acquired immune response. Science 272: 50–53PubMedCrossRefGoogle Scholar
  3. 3.
    Rook GA, Stanford JL (1998) Give us this day our daily germs. Immunol Today 19: 113–116PubMedGoogle Scholar
  4. 4.
    Steel DM, Whitehead AS (1994) The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 15: 81–88Google Scholar
  5. 5.
    Xu L, Badolato R, Murphy WJ, Longo DL, Anver M, Hale S, Oppenheim JJ, Wang JM (1995) A novel biologic function of serum amyloid A (SAA). Induction of T lymphocyte migration and adhesion. J Immunol 155: 1184–1190Google Scholar
  6. 6.
    Preciado-Patt L, Hershkovitz R, Fridkin M, Lider O (1996) Serum amyloid A binds specific extracellular matrix glycoproteins and induces adhesion of resting CD4 T cells. J Immunol 156: 1198–1205Google Scholar
  7. 7.
    Ristori G, Laurenti F, Stacchini P, Gasperini C, Buttinelli C, Pozzilli C, Salvetti M (1998) Serum amyloid A protein is elevated in relapsing-remitting multiple sclerosis. J Neuroimmunol 88: 9–12PubMedCrossRefGoogle Scholar
  8. 8.
    Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA (1994) Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 179: 973–984PubMedCrossRefGoogle Scholar
  9. 9.
    Allegretta M, Nicklas JA, Sriram S, Albertini RJ (1990) T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247: 718721Google Scholar
  10. 10.
    Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA (1992) y8 T cell receptor in acute multiple sclerosis lesions. Proc Natl Acad Sci USA 89: 4588–4592Google Scholar
  11. 11.
    Triebel F, Hercend T (1989) Subpopulations of human peripheral y8 T lymphocytes. Immunol Today 10: 186–188PubMedCrossRefGoogle Scholar
  12. 12.
    Selmaj K, Brosnan CF, Raine CS (1991) Co-localization of lymphocytes bearing y8 T cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis. Proc Natl Acad Sci USA 88: 6452–6456PubMedCrossRefGoogle Scholar
  13. 13.
    Battistini L, Selmaj K, Kowal C, Ohmen J, Modlin RL, Raine CS, Brosnan CF (1995) Multiple sclerosis: limited diversity of the V82–J83 T cell receptor in chronic active lesions. Ann Neurol 37: 198–203PubMedCrossRefGoogle Scholar
  14. 14.
    Freedman MS, Ruijs TCG, Selin LK, Antel JP (1991) Peripheral blood y-8 T cells lyse fresh human brain-derived oligodendrocytes. Ann Neurol 30: 794800Google Scholar
  15. 15.
    Battistini L, Fisher F, Raine CS, Brosnan CF (1996) CD lb expression in multiple sclerosis. J Neuroimmunol 67: 145–151PubMedGoogle Scholar
  16. 16.
    Battistini L, Borsellino G, Sawicki G, Poccia F, Salvetti M, Ristori G, Brosnan CF (1997) Phenotypic and cytokine analysis of human peripheral blood yd T cells expressing NK cell receptor. J Immunol 159: 3723–3730PubMedGoogle Scholar
  17. 17.
    Poggi A, Zocchi MR, Costa P, Ferrero E, Borsellino G, Placido R, Galgani S, Salvetti M, Gasperini C, Ristori G, Brosnan CF, Battistini L (1999) IL-12mediated NKRP1A up-regulation and consequent enhancement of endothelial transmigration of V82+ TCRy+ T lymphocytes from healthy donors and multiple sclerosis patients. J Immunol (in press)Google Scholar
  18. 18.
    Poggi A, Costa P, Zocchi MR, Moretta L (1997) Phenotypic and functional analysis of CD4+ NKRP1A human T lymphocytes: direct evidence that the NKRP1A molecule is involved in transendothelial migration. Eur J Immunol 27: 2345–2350PubMedCrossRefGoogle Scholar
  19. 19.
    Lewin B (1993) Genes V. Oxford University, OxfordGoogle Scholar
  20. 20.
    Fischer Lindahl K, Byers DE, Dahbi VM, Hovik R, Jones EP, Smith GP, Wang CR, Xiao H, Yoshino M (1997) H2–M3, a full-service class Ib histocompatibility antigen. Annu Rev Immunol 15: 851–879CrossRefGoogle Scholar
  21. 21.
    Shirakawa T, Enomoto T, Shimazu S, Hopkin JM (1997) The inverse association between tuberculin response and atopic disorder. Science 275: 77–79PubMedCrossRefGoogle Scholar
  22. 22.
    Ristori G, Buttinelli C, Pozzilli C, Fieschi C, Salvetti M (1999) Microbe exposure, innate immunity and autoimmunity. Immunol Today (in press)Google Scholar
  23. 23.
    Shehadeh N, Calcinaro F, Bradley BJ, Bruchlim I, Vardi P, Lafferty KJ (1994) Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 343: 706–707PubMedCrossRefGoogle Scholar
  24. 24.
    Pozzilli P, on behalf of the IMDIAB Group (1997) BCG vaccine in insulin-dependent diabetes mellitus. Lancet 349: 1520–1521Google Scholar
  25. 25.
    Miller DH, Alpert PS, Barkhof F, Frances G, Frank JA, Hodgkinson S, Lublin FD, Paty DW, Reingold SC, Simon J (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 39: 6–16Google Scholar

Copyright information

© Springer-Verlag Italia, Milan 1999

Authors and Affiliations

  • G. Ristori
  • A. Perna
  • C. Montesperelli
  • L. Battistini
  • R. Bomprezzi
  • S. Cannoni
  • G. Borsellino
  • C. Pozzilli
  • C. Buttinelli
  • M. Salvetti

There are no affiliations available

Personalised recommendations